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A dysfunctional glutamatergic system is thought to be central to the negative symptoms and cognitive
deﬁcits recognized as determinant to the poor quality of life of people with schizophrenia. Modulating
glutamate uptake has, thus, been suggested as a novel target for antipsychotics. Alstonine is an indole
alkaloid sharing with atypical antipsychotics the proﬁle in animal models relevant to schizophrenia,
though divergent in its mechanism of action. The aim of this study was to evaluate the effects of alstonine
on glutamate uptake. Additionally, the effects on glutathione content and extracellular S100B levels were
assessed. Acute hippocampal slices were incubated with haloperidol (10 lM), clozapine (10 and 100 lM)
or alstonine (1–100 lM), alone or in combination with apomorphine (100 lM), and 5-HT2 receptor antag-
onists (0.01 lM altanserin and 0.1 lM SB 242084). A reduction in glutamate uptake was observed with
alstonine and clozapine, but not haloperidol. Apomorphine abolished the effect of clozapine, whereas 5-
HT2A and 5-HT2C antagonists abolished the effects of alstonine. Increased levels of glutathione were
observed only with alstonine, also the only compound that failed to decrease the release of S100B. This
study shows that alstonine decreases glutamate uptake, which may be beneﬁcial to the glutamatergic
deﬁcit observed in schizophrenia. Noteworthily, the decrease in glutamate uptake is compatible with
the reversal of MK-801-induced social interaction and working memory deﬁcits. An additional potential
beneﬁt of alstonine as an antipsychotic is its ability to increase glutathione, a key cellular antioxidant
reported to be decreased in the brain of patients with schizophrenia. Adding to the characterization of
the novel mechanism of action of alstonine, the lack of effect of apomorphine in alstonine-induced
changes in glutamate uptake reinforces that D2 receptors are not primarily implicated. Though clearly
mediated by 5-HT2A and 5-HT2C serotonin receptors, the precise mechanisms that result in the effects
of alstonine on glutamate uptake warrant elucidation.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction prompted the idea of a glutamatergic dysfunction in the patho-With lifetime prevalence commonly estimated in 1% of the pop-
ulation, schizophrenia is a severe psychiatric disorder marked by
profound retreat from reality and incapacitating cognitive deﬁcits.
It belongs to a group of complex multifactorial disorders, for which
the etiology is understood as the intricate interaction between ge-
netic and environmental factors (Gogos and Gerber, 2006; van Os
et al., 2010).
The observations of the behavioral effects induced by phencyc-
lidine (PCP), an antagonist of glutamate NMDA receptors,sicas da Saúde, Universidade
0, sala 202, 90050-170 Porto
rrmann).
sevier OA license.physiology of schizophrenia. PCP, as well as the related drugs
ketamine and MK-801, induce in normal volunteers psychosis-like
and neurocognitive disturbances similar to those of schizophrenia;
unlike dopaminergic agonists, these drugs mimic all the symptoms
dimensions of the disease (Javitt, 2010). It is now widely accepted
that the dopaminergic alterations classically associated to schizo-
phrenia may, in fact, be secondary to an underlying deﬁcit in gluta-
matergic transmission (Carlsson, 2006; Marek et al., 2010). Of note,
Stone et al. (2010) reported in prodromic subjects with mild psy-
chotic symptoms a negative relationship between hippocampal
glutamate levels and striatal [18F]-DOPA uptake, reinforcing the
idea of a coupling between glutamatergic transmission and striatal
dopaminergic activity.
Glutamate is released into the synapse and rapidly removed by
a family of excitatory amino acid transporters (EAATs) localized in
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ﬁed and termed EAAT1–5 to human homologs, or GLAST, GLT-1
and EAAC-1 representing the rodent homologs of EAATs1–3,
respectively (Kanai and Hediger, 1992; Pines et al., 1992; Storck
et al., 1992; Fairman et al., 1995; Arriza et al., 1997). EAAT2/
GLT-1 is predominantly expressed in astrocytes and provides more
than 90% of total glutamate uptake in the central nervous system
(Tanaka et al., 1997).
Given that astrocytes are fundamental in the control of gluta-
mate homeostasis, a signiﬁcant role has recently been assigned
to glial–neuronal interactions in the pathophysiology of schizo-
phrenia. There is increasing evidence that structural and functional
alterations in glial cells are present in the brain of people with
schizophrenia (Cotter et al., 2001; Kondziella et al., 2006; Bernstein
et al., 2009; Katsel et al., 2011). Additionally, a DNA array study
showed that the genes most frequently altered in the disorder
are related to glial function (Sugai et al., 2004). Signaling mole-
cules, such as S100B and GFAP, have also been examined as mark-
ers of astrocytic function. Several studies reported increased S100B
levels in the serum or cerebrospinal ﬂuid (CSF) of patients with
schizophrenia (Wiesmann et al., 1999; Lara et al., 2001; Rother-
mundt et al., 2001, 2004a,b, 2007; Schroeter et al., 2003; Schmitt
et al., 2005); however, the effects of antipsychotic drugs in this
parameter remain unclear (Steiner et al., 2010).
It is undisputable that over the past decades major advances
have been accomplished in the understanding of the neurobiologi-
cal processes involved in schizophrenia. The acquired knowledge,
however, has not translated into better treatment options, since
all currently available antipsychotics share their mechanism of ac-
tion with drugs discovered almost 60 years ago. Moreover, the
modest and controversial beneﬁts of antipsychotics on cognitive
deﬁcits and negative symptoms, combined with the unwanted side
effects, result in high rates of treatment discontinuation (Lieber-
man et al., 2005). The development of drugs with innovative mech-
anisms of action is, thus, required (Gründer et al., 2009).
We have previously reported the properties of alstonine, a puta-
tive antipsychotic which has consistently shown anxiolytic and
antipsychotic-like effects in several mouse models (Costa-Campos
et al., 1998, 2004a; de Moura Linck et al., 2008). Alstonine is an in-
dole alkaloid present in plant species traditionally used in Nigeria
to treat mentally ill patients (Costa-Campos et al., 1998). Although
its mechanism of action remains unclear, D2 receptors do not seem
to be directly involved in its antipsychotic-like effects, and block-
ade of 5-HT2A/C receptors by ritanserin abolished its anxiolytic ac-
tion (Costa-Campos et al., 2004a). Recent data showed that the
ability of alstonine to counteract MK-801-induced working mem-
ory deﬁcit, social withdrawal and hyperlocomotion was also
blocked by pretreatment with ritanserin (Linck et al., 2012).
Considering the growing role attributed to astrocytes in brain
signaling and the recognized association between glutamatergic
dysfunction and schizophrenia, the aim of this study was to evalu-
ate the effects of alstonine on glutamate uptake and other astro-
cytic parameters. The effects of alstonine were compared to
typical and atypical antipsychotics (haloperidol and clozapine,
respectively). For this purpose, we used acute hippocampal slices,
elected for preserving the neuronal circuitry and the interactions
between neurons and glia.2. Materials and methods
2.1. Animals
Experiments were performed with 30-day-old male Wistar rats
obtained from our breeding colony (Department of Biochemistry,
UFRGS, Porto Alegre, Brazil). Animals were maintained undercontrolled environmental conditions (12-h light/dark cycle at a
constant temperature of 22 ± 1 C) with free access to food and
water. The study was approved by the University Ethics Committee
(approval #18237), and followed institutional policies on experi-
mental animal handling. All efforts were made to minimize animal
suffering, to reduce the number of animals used, and to utilize
alternatives to in vivo techniques.
2.2. Drugs and reagents
Alstonine hydrochloride was isolated from Picralima nitida Th. &
H. Dur. (Apocynaceae) by Christopher O. Okunji, as earlier de-
scribed (Okunji et al., 2005). Clozapine, altanserin and SB 242084
were purchased from Sigma Chemical Co. (St. Louis, MO, USA),
apomorphine was purchased from Research Biochemicals Interna-
tional (Natick, MA, USA), DL-threo-b-benzyloxyaspartic acid
(DL-TBOA) was acquired from Tocris Bioscience (Bristol, UK) and
haloperidol was used as commercial Haldol from Janssen-Cilag
Farmacêutica Ltd. (São Paulo, SP, Brazil). Monoclonal anti-S100B
antibody (SHB1), 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic
acid (Hepes), o-phenylenediamine (OPD), 3-(4,5-dimethylthiazol-
yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and L-glutamate
were purchased from Sigma (St. Louis, MO, USA), polyclonal rabbit
anti-S100 from Dako (Glostrup, Denmark), and horseradish perox-
idase-conjugated anti-rabbit IgG and L-[2,3-3H]-glutamate from
Amersham International (Buckinghamshire, UK). All other chemi-
cals were purchased from local commercial suppliers.
2.3. Hippocampal slices
Rats were killed by decapitation. Hippocampi were removed
and sliced in transverse sections of 0.3 mm using a McIlwain tissue
chopper. Slices were transferred to 24-well plates containing
0.3 mL of Hepes-buffered saline solution (120 mM NaCl, 2 mM
KCl, 1 mM CaCl2, 1 mM MgSO4, 1 mM KH2PO4, 10 mM glucose
and 25 mM Hepes, pH 7.4) per well. The medium was changed
every 15 min for 2 h at room temperature. After this stabilization
period, the drugs were added and the slices incubated for 1 h at
30 C. Treatments consisted of haloperidol (10 lM), clozapine (10
and 100 lM), alstonine (1, 10 and 100 lM), apomorphine
(100 lM), altanserin (0.01 lM) and SB 242084 (0.1 lM). Drug con-
centrations were chosen based on pilot experiments and/or previ-
ous reports (Steiner et al., 2010; Nardin et al., 2011). All
experiments were performed in triplicate (three slices from the
same animal were used for each treatment condition).
2.4. Glutamate uptake
After the incubation period, the medium was replaced by
Hank’s balanced salt solution (HBSS) containing 137 mM NaCl,
0.63 mM Na2HPO4, 4.17 mM NaOHCO3, 5.36 mM KCl, 0.44 mM
KH2PO4, 1.26 mM CaCl2, 0.41 mM MgSO4, 0.49 mM MgCl2 and
5.55 mM glucose, pH 7.4. The slices were maintained at 35 C,
and the assay was started by adding 0.1 mM L-glutamate and
0.66 lCi/mL L-[2,3-3H]-glutamate; this high unlabeled glutamate
concentration renders the assay insensitive to changes in gluta-
mate release. Incubation was stopped after 5 min by removing
the medium and rinsing the slices three times with ice-cold HBSS;
it has been shown that up to 5 min the glutamate uptake is linear
in this slice preparation (Thomazi et al., 2004). Slices were then
lysed in a solution containing 0.5 N NaOH. Sodium-independent
(nonspeciﬁc) uptake was determined using a solution with N-
methyl-D-glutamine instead of NaCl. Sodium-dependent glutamate
uptake was obtained by subtracting nonspeciﬁc uptake. Radioac-
tivity was measured with a scintillation counter (2800TR TriCarb
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nal glutamate uptake was expressed as nmol/mg protein/min.
As an indication that most of the sodium-dependent uptake in
this slice preparation is glutamate transporter-dependent, 75% of
the uptake was inhibited by the transporter blocker DL-TBOA
(300 lM), in comparison to 85% inhibition in sodium-free condi-
tions (basal: 6463 ± 699, sodium-free: 940 ± 185, 300 lM DL-
TBOA: 1613 ± 161, in cpm, data not shown).2.5. Glutathione content
Total reduced glutathione content was determined as previ-
ously described (Browne and Armstrong, 1998). Brieﬂy, slices
were homogenized in sodium phosphate buffer (0.1 M, pH 8.0)
containing 5 mM EDTA and protein was precipitated with 1.7%
meta-phosphoric acid. Supernatant was assayed with o-phthaldial-
dehyde (1 mg/ml of methanol) at room temperature for 15 min.
Fluorescence was measured using excitation and emission wave-
lengths of 350 and 420 nm, respectively. A calibration curve was
performed with standard glutathione solutions (0–500 lM). Final
concentrations were calculated and expressed as nmol/mg protein.2.6. Extracellular S100B content
Immediately after the incubation period, 10 lL of medium were
collected and kept in20 C until S100B levels were determined by
ELISA, as previously described (Leite et al., 2008). Brieﬂy, 50 lL of
Tris buffer were added to the samples and incubated for 2 h in a
microtiter plate previously coated with monoclonal anti-S100B.
Polyclonal anti-S100 was incubated for 30 min; peroxidase-
conjugated anti-rabbit antibody was added for additional 30-min
incubation. The color reaction with o-phenylenediamine was mea-
sured at 492 nm. The standard S100B curve ranged from 0.002 to
1 ng/mL. Results were expressed as a percentage of the control.2.7. Cell viability and integrity
Cell viability was assayed by the colorimetric MTT reduction
method (Hansen et al., 1989). Brieﬂy, slices were incubated with
0.5 mg/mL of MTT at 30 C for 30 min. The formazan product gen-
erated during the incubation was solubilized in dimethyl sulfoxide
(DMSO). Absorbance values were measured at 560 and 630 nm.
Cell integrity was indicated by lactate dehydrogenase (LDH) activ-
ity in the incubation medium. Determination was carried out by a
colorimetric commercial kit (Doles Reagentes e Equipamentos para
Laboratórios Ltd., Brazil) according to the manufacturer’s instruc-
tions. Results were expressed as percentage of the control.2.8. Protein content
Total protein concentrations were determined by the modiﬁed
method of Lowry (Peterson, 1977), using bovine serum albumin
as standard.Fig. 1. Effects of haloperidol (Hal), clozapine (Clz) and alstonine (Alst) on cell
viability and integrity. (A) MTT reduction to formazan. (B) Activity of lactate
dehydrogenase released into the medium. Hippocampal slices were incubated for
1 h with the various drugs at the indicated concentrations. Data represent
mean + SEM and are expressed as percentage of control. One-way ANOVA.2.9. Statistical analysis
Data were analyzed by one-way ANOVA followed by Newman–
Keuls post hoc test. Two-way ANOVA was employed when analyz-
ing the effects of two independent variables. GraphPad Prism 5 for
Windows was used for the statistical analysis; p < 0.05 was set as
statistically signiﬁcant. Results represent mean + SEM.3. Results
In order to verify if cell viability (Fig. 1A) and integrity (Fig. 1B)
were not compromised by drug treatments, two assays were per-
formed in parallel; no signiﬁcant differences were observed for
MTT reduction (F6, 53 = 2.15, p > 0.05) or LDH activity (F6, 56 = 0.25,
p > 0.05), indicating that slices remained viable and integrate.
These same parameters were also evaluated for apomorphine,
altanserin and SB 242084, with no signiﬁcant alterations (data
not shown).
Glutamate uptake in hippocampal slices was signiﬁcantly
(F6, 55 = 8.63, p < 0.0001) altered by treatments (Fig. 2A). Post hoc
analysis revealed that 10 and 100 lM clozapine and alstonine sig-
niﬁcantly decreased glutamate uptake (49% and 59%, respectively,
at highest concentrations). The co-incubation of the drugs with
100 lM apomorphine also affected glutamate uptake (F7, 50 = 9.83,
p < 0.0001), as shown in Fig. 2B. Post hoc analysis indicated that
apomorphine had no effects per se, and did not interfere with alst-
onine-induced decrease in glutamate uptake; interestingly, how-
ever, the decrease in glutamate uptake induced by clozapine at
100 lM was abolished in the presence of apomorphine.
The role of 5-HT2A and 5-HT2C receptors on alstonine-induced
reduction of glutamate uptake was investigated. Two-way ANOVA
revealed a main effect of 100 lM alstonine (F1, 26 = 11.79, p < 0.01),
and of the 5-HT2A antagonist altanserin (F1, 26 = 4.23, p < 0.05), as
well as interaction between alstonine and altanserin
(F1, 26 = 14.25, p < 0.001) (Fig. 3A). Two-way ANOVA also revealed
a main effect of 100 lM alstonine (F1, 26 = 71.89, p < 0.01) and of
the 5-HT2C antagonist SB 242084 (F1, 26 = 7.46, p < 0.05), as well
as interaction between alstonine and SB 242084 (F1, 26 = 40.46,
p < 0.001) (Fig. 3B). These results show that the effect of alstonine
on glutamate uptake involve both 5-HT2A and 5-HT2C receptors.
Fig. 2. Effects of haloperidol (Hal), clozapine (Clz), alstonine (Alst) and apomor-
phine (Apo) on glutamate uptake in hippocampal slices. (A) Glutamate uptake after
incubation with the drugs per se. (B) Glutamate uptake after co-incubation of drugs
and apomorphine. Data represent mean + SEM and are expressed as nmol/mg
protein/min.  = p < 0.05,  = p < 0.01,  = p < 0.001 compared to control. One-
way ANOVA/Newman–Keuls.
Fig. 3. Effects of 5-HT2A and 5-HT2C receptor antagonists on alstonine-induced
decrease in glutamate uptake. Glutamate uptake after co-incubation of 100 lM
alstonine with 0.01 lM altanserin (A) and 0.1 lM SB 242084 (B). Data represent
mean + SEM and are expressed as nmol/mg protein/min.  = p < 0.01 compared to
control. Two-way ANOVA/Newman–Keuls.
Fig. 4. Effects of haloperidol (Hal), clozapine (Clz) and alstonine (Alst) on
glutathione content. Hippocampal slices were incubated for 1 h with the drugs
and total glutathione content was measured. Data represent mean + SEM and are
expressed as nmol/mg protein.  = p < 0.05 compared to control. One-way ANOVA/
Newman–Keuls.
Fig. 5. Effects of haloperidol, clozapine and alstonine on S100B secretion. Hippo-
campal slices were incubated for 1 h with the drugs and S100B levels in the
medium were measured. Data represent mean + SEM and are expressed as
percentage of control. =p < 0.05 compared to control. One-way ANOVA/New-
man–Keuls.
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campal slices submitted to drug treatments (F6, 50 = 3.76,
p < 0.01), as shown in Fig. 4. Post hoc analysis indicated that onlyalstonine in its highest concentration (100 lM) was able to in-
crease (70%) glutathione levels in comparison to control.
As shown in Fig. 5, treatment with antipsychotic drugs signiﬁ-
cantly altered S100B secretion (F6, 133 = 3.15, p < 0.01). Post hoc
analysis revealed that haloperidol at 10 lM and clozapine at 100,
but not 10 lM, reduced (29% and 25%, respectively) the secretion
of this protein.4. Discussion
In the present study, we show the effects of the alkaloid alsto-
nine and known antipsychotics in biochemical parameters relevant
to the pathophysiological basis of schizophrenia. One signiﬁcant
ﬁnding is the observation that alstonine and clozapine, but not hal-
operidol, reduced glutamate uptake in acute hippocampal slices.
Though the mechanism by which glutamate uptake is reduced re-
quires further clariﬁcation, a generalized effect on sodium gradi-
ents seems unlikely given the absence of evidence that
antipsychotics induce changes in Na+, K+-ATPase activity or mem-
branes sodium gradients (Seibt et al., 2012; López Ordieres et al.,
2005), as well as the reversal seen with the serotonin antagonists.
Speciﬁcally for alstonine, no changes in dopamine or serotonin lev-
els were seen in the striatum from mice acutely treated with alst-
onine in behaviorally effective doses (Linck et al., 2011), again
arguing against a generalized effect that would also alter the so-
dium-dependent monoamine transporters. The nearly complete
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inhibitor TBOA advances the idea that it is the high-afﬁnity so-
dium-dependent glutamate transport that was evaluated in this
study.
It is known that it is the glutamate transport by astrocyte that
determines the availability of released glutamate to pre- and
post-synaptic receptors, as well as its spillover to extra-synaptic
sites (Diamond, 2001; Huang and Bergles, 2004; Huang et al.,
2004; Dunlop et al., 2006). Several studies have documented al-
tered expression and function of astrocytic glutamate transporters
in schizophrenia (Ohnuma et al., 1998, 2000; Smith et al., 2001;
Matute et al., 2005), and it has been suggested that an increased
glutamate uptake by astrocytes may considerably contribute to
its purported glutamatergic hypofunction (Nanitsos et al., 2005).
Reducing glutamate uptake can, thus, be regarded as a viable strat-
egy to improve glutamatergic function, and is compatible with the
ability of alstonine and clozapine to counteract MK-801-induced
behavioral effects. In agreement with our ﬁndings, it has been pre-
viously reported that clozapine reduced both the expression of the
GLT-1 glutamate transporter and the glutamate uptake in astrocyte
cultures (Vallejo-Illarramendi et al., 2005), as well as the glutamate
transport in rat prefrontal cortex (Melone et al., 2003). Moreover,
the atypical antipsychotic aripiprazole decreased the gene expres-
sion of glial and neuronal glutamate transporters in cortical and
hippocampal regions, suggesting a transcriptional mechanism to
strengthen glutamatergic transmission (Segnitz et al., 2009). On
the contrary, selective D2 receptor antagonists, such as haloperidol,
were shown to be less effective than atypical antipsychotics to
attenuate the effects induced by NMDA receptor antagonists
(Meltzer et al., 2011), in agreement with the lack of effects of
haloperidol on glutamate uptake. It remains to be clariﬁed which
subtypes of transporters are altered by alstonine, as well as if the
mechanism is common to the atypical agents above mentioned.
Although reducing glutamate uptake can be advantageous to
minimize glutamatergic hypofunction and is suggested as a novel
target for antipsychotics (Nanitsos et al., 2005), it is well estab-
lished that excessive glutamate availability may overactivate
NMDA and AMPA receptors leading to excitotoxicity. In the case
of alstonine, the glutamatergic modulation through reduced up-
take does not seem to reach excitotoxic levels, since unlike cloza-
pine alstonine lacks proconvulsant properties in a kindling
paradigm (Costa-Campos et al., 2004b). Congruent with the
evidence that alstonine lacks afﬁnity for dopamine receptors
(Costa-Campos et al., 1998), the co-incubation with the dopamine
agonist apomorphine did not alter the alstonine-induced decrease
in glutamate uptake, but abolished that of clozapine.
Save for dopamine and glutamate, it has been shown that some
atypical antipsychotics act as 5-HT2A/C receptor antagonists and/or
inverse agonists (Meltzer et al., 2011). This serotonergic modula-
tion is thought to be decisive for the alleged advantages of these
medications over classical agents (Gründer et al., 2009). However,
agonists of these receptors may also present a desirable antipsy-
chotic-proﬁle, since activation of 5-HT2A receptors enhances dopa-
mine release, whereas 5-HT2C activation inhibits it (Bortolozzi
et al., 2005; Di Giovanni et al., 2006; Pehek et al., 2006; Huang
et al., 2011). Several groups have demonstrated that astrocytes ex-
press various 5-HT receptor subtypes, including 5-HT2A and 5-HT2C
(Deecher et al., 1993; Merzak et al., 1996; Hirst et al., 1998; Cohen
et al., 1999). One known effect of serotonin and selective serotonin
reuptake inhibitors at these receptors is the elevation of intracellu-
lar calcium levels in glial cells (Hagberg et al., 1998; Schipke et al.,
2011), which was shown to trigger the efﬂux of glutamate (Meller
et al., 2002). It is conceivable that changes in astrocytic glutamate
uptake may also result from changes in calcium levels when these
serotonin receptors are modulated. We here show that alstonine-
induced decrease in glutamate uptake is prevented by bothaltanserin and SB 242084, consistent with the ability of ritanserin
to prevent the behavioral effects of alstonine (Costa-Campos et al.,
2004a; Linck et al., 2012). The proposal that serotonin is associated
with alstonine mechanism of action is also supported by the in-
creased levels of serotonin and 5-HIAA in frontal cortex and stria-
tum from alstonine treated mice (Linck et al., 2011). Though it is
clear that alstonine modulates serotonin pathways, it remains to
be clariﬁed whether alstonine activates receptors, increases seroto-
nin release, or both. Likewise, since 5-HT2A/C receptors are ex-
pressed in both neurons and astrocytes, data from cultured
astrocytes controlled for the expression of EAAT1/EAAT2 would
better clarify if glutamate transport is affected in neurons, astro-
cytes or both. Most importantly, the congruence from in vitro
and in vivo data shows that whatever the speciﬁc transport af-
fected, glutamatergic transmission is signiﬁcantly modulated by
alstonine.
Glutathione is a tripeptide consisting of glycine, cysteine and
glutamate, which participates in essential aspects of cellular
homeostasis. The cellular ability to synthesize glutathione is an
important factor in the management of oxidative stress-induced
neurotoxicity. Schizophrenia has been consistently associated with
reduced levels of glutathione, leading to potential NMDA receptors
dysfunction (Do et al., 2000; Steullet et al., 2006; Yao et al., 2006;
Gysin et al., 2007; Matsuzawa et al., 2008; Raffa et al., 2009;
Gawryluk et al., 2011; Micó et al., 2011). Our results show that,
among the antipsychotics studied, only alstonine was able to in-
crease the intracellular levels of glutathione in hippocampal slices;
this may represent an additional valuable feature of alstonine. The
alstonine-induced increment in glutathione content could result
from increased synthesis, regeneration (NADPH-dependent),
sparing or decreased exportation by astrocytes (for a review see
Hirrlinger and Dringen, 2010). Additional experiments, including
those with astrocyte cultures, are required to elucidate the precise
mechanism(s) by which alstonine increases glutathione.
S100B is a calcium-binding protein secreted by astrocytes into
the synapse, where it is thought to participate in synaptic plasticity
(Nishiyama et al., 2002), being neurotrophic at nanomolar and
apoptotic at micromolar levels (Ahlemeyer et al., 2000; Kögel
et al., 2004). Increased serum and CSF S100B levels in patients with
schizophrenia have been interpreted as a marker of structural
damage or, alternatively, as a sign of increased astrocyte activation
(Wiesmann et al., 1999). It has been suggested that antipsychotic
drugs could normalize these elevated levels (Ling et al., 2007;
Steiner et al., 2009, 2010; Nardin et al., 2011). Consistent with
results obtained by Steiner et al. (2010) in C6 and OLN-93 cell cul-
tures, we here show that both the typical antipsychotic haloperidol
and the atypical clozapine decreased the release of S100B in hippo-
campal slices. In contrast, alstonine did not alter S100B levels,
again reinforcing differences in receptor targets between alstonine
and known antipsychotics. Considering that the mechanism of
S100B secretion remains unclear, it is of interest to evaluate the
effects of alstonine in S100B levels under pharmacological condi-
tions of dopaminergic activation before the meaning of this result
can be properly addressed.5. Conclusions
The key ﬁnding of this study is the decrease in glutamate uptake
induced by alstonine, and its mediation by 5-HT2A and 5-HT2C
receptors. A growing body of evidence suggests that particularly
the cognitive and negative symptoms of schizophrenia result from
a dysfunctional glutamatergic system. Consequently, decreasing
glutamate uptake may represent an important feature for develop-
ing newer antipsychotic medication, especially effective in the
symptoms that are currently undertreated.
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